Back to results
US 8,557,745 B2Granted
Markers and methods for assessing and treating Crohn's and related disorders
AssigneeJanssen Biotech, Inc.
InventorsMarion Blank, Gary Toedter
Life of this patent
Estimating the term…
Abstract
A method for assessment of the suitability of and/or effectiveness of a target therapy for a gastrointestinal-related disorder, such as Crohn's disease, in a subject evaluates the presence, absence, and/or magnitude of expression of one or more genes in a 10-member gene panel in a sample. The method enables identification of the effectiveness of target therapies prior to or after starting a patient on such therapies.
Claims9
A method for predicting the suitability of treatment with an anti-IL-12 antibody therapy for Crohn's disease in a subject, comprising:
- a) preparing a sample of nucleic acids from a specimen obtained from the subject;
- b) contacting the sample with a panel of nucleic acid segments consisting of at least a portion of the nucleotide sequences corresponding to SEQ ID NOS:1-10 to detect levels of the panel segments;
- c) evaluating the sample against a reference standard to determine the magnitude of change in the amounts of the portions of the nucleotide sequences present in the sample;
- d) correlating the magnitude of change with the suitability of treatment with anti-IL-12 antibody therapy for Crohn's disease;
- and
- e) treating or refraining from treating the subject based on the correlation of suitability of treatment.
3 more elements
Dependencies are inferred from the claim text.